A fun study is recognized as, “Intrapulmonary localized fibrous tumor. Intraparenchymal so-called localized fibrous mesothelioma.” By Yousem SA, Flynn SD – Am J Clin Pathol. 1988 Mar;89(3):365-9. The following is an excerpt: “Abstract – This report describes three installments of intrapulmonary fibromas which are usually histologically comparable to localized fibrous tumors of pleura (localized fibrous mesothelioma). Morphologically these tumors are observed as a haphazard proliferation of cytologically bland spindle cells separated by variable amounts of wavy hyalinized collagen. Entrapped bronchiolar and alveolar epithelium is normal. These spindle cells lack expression of cytoplasmic keratin, S-100 protein, desmin, and epithelial membrane antigen, however they are strongly decorated for intracellular vimentin. The clinical behavior, differential diagnosis, and histogenesis these lesions are discussed.” Another interesting study is known as, “Posttranscriptional regulation of urokinase receptor mRNA: identification of the novel urokinase receptor mRNA binding protein in human mesothelioma cells” by S Shetty, A Kumar and S Idell – Department of medication, University of Texas Health Science Center, Tyler 75710, USA. Mol. Cell. Biol., 03 1997, 1075-1083, Vol 17, No. 3 American Society for Microbiology. The following is an excerpt: “Treatment of human pleural mesothelioma (MS-1) cells with phorbol myristate acetate (PMA) and cycloheximide results in 17- and 10-fold, respectively, increases in steady-state expression of urokinase-type plasminogen activator receptor (uPAR) mRNA. Studies of transcriptional inhibition by actinomycin D showed four- and sixfold extensions of uPAR mRNA half-life in MS-1 cells addressed with PMA and cycloheximide, respectively, suggesting that uPAR gene expression involves a posttranscriptional regulatory mechanism. Using gel mobility shift and UV cross-linking assays, we identified a 50-kDa uPAR mRNA binding protein (uPAR mRNABp) that selectively restricted by a 51-nucleotide (nt) fragment of mRNA corresponding to the uPAR coding region. We investigated the chance that this 51-nt protein binding fragment of uPAR mRNA contains regulatory information for message stability. Chimeric beta-globin/uPAR/beta-globin mRNA containing the 51-nt protein binding fragment surely could destabilize otherwise stable beta-globin mRNA. Conversely, a control chimeric beta-globin/uPAR/beta-globin mRNA containing a 51-nt fragment from the uPAR coding region that won’t bind uPAR mRNABp was stable under identical conditions. Binding of uPAR mRNABp to uPAR mRNA was abolished after treatment with cycloheximide and rapidly down-regulated by PMA. These data suggest that the 51-nt protein binding fragment of uPAR mRNA could possibly be linked to mRNA turnover as well as in cycloheximide-induced uPAR message stabilization. Our results indicate a singular mechanism of uPAR gene regulation that cis elements inside of a 51-nt coding region interact with a uPAR mRNABp to modify uPAR message stability.”
One interesting study is named, “Good relief of symptoms with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant Mesothelioma” – Oxford Journals Medicine Annals of OncologyVolume9, Issue 3 Pp. 269-273 by G. W. Middleton, I. E. Smith, M. E. R. O’Brien, A. Norton, T. Hickish, K. Priest, L. Spencer and S. Ashley This is an excerpt: “Abstract – Purpose: To guage the therapeutic impact of your simple combination chemotherapy regimen on symptoms related to malignant mesothelioma. Materials and techniques: Between October 1986 and June 1997, 39 patients with advanced inoperable malignant mesothelioma were given palliative MVP (mitomycin-C 8 mg/ m q. six or seven weeks, vinblastine 6 mg/2 q. three weeks and cisplatin 50 mg/m2 q. 3 weeks) chemotherapy and assessed for objective response and relief of symptoms. Results: Eight of 39 patients (20%) achieved an intention partial response by using a median length of nine months: only five patients had progression of disease during chemotherapy. Twenty-four of 39 (62%) had a generally improvement with their symptomology with particularly good responses for pain (79%). These benefits were outside of performance status. Resolution of symptoms was achieved in every responding patients within two treatment cycles. There wasn’t any statistically factor in duration and incidence of symptom response in those patients achieving radiological PR in comparison with people with no change and over 60% of patients with radiological no change obtained useful symptom control. Treatments was well tolerated with only four patients developing grade 3 leucopenia and three with grade 3 nausea. Conclusions: MVP is actually a well tolerated regimen as well as utilize in malignant mesothelioma provides useful symptomatic benefit. These results management of cause of further trials of MVP inside cure for mesothelioma with symptom control as being a principal endpoint.
Everyone owe a debt of gratitude in order to those fine researchers. In case you found some of these excerpts interesting, please check the studies for their entirety. Monty Wrobleski could be the author informed. To read more please select the following links Mesothelioma Attorney Mesothelioma Lawyer Mesothelioma Lawyer
No comments:
Post a Comment